The prothrombin gene mutation is a risk factor of many complications (miscarriage, fetoplacental insufficiency, intrauterine fetal demise, gestosis, fetal growth restriction and placental abruption). The mutation frequency in patients with early and late miscarriages is 4.2% and 3% respectively.
It is one of the main factors of the blood coagulation system. The presence of the “risk” allele A increases a prothrombin level in plasma by 30%; it increases the risk of venous thrombosis, ischemic stroke and thromboembolism (three-fold).
Mutations of F2 and F5 genes (II and V blood coagulation factors) pose a serious risk to women taking oral contraceptives. The risk allele A of any of these genes can be the basis for the development of thrombosis of lower extremities’ veins and the cerebral (brain) vessels, arterial thrombosis at a young age, an ischemic stroke and pregnancy disruption. In women taking hormonal contraceptives, the risk of thrombosis with the AA genotype is increased by 30 times and with the GA genotype – by 6-9 times. The use of oral contraceptives is indicated in the case of normal GG genotypes by both genes.
It is one of the main factors of the blood coagulation system. The presence of the “risk” allele A increases a prothrombin level in plasma by 30%; it increases the risk of venous thrombosis, ischemic stroke and thromboembolism (three-fold).